British Regulator Declares Cannabis Compound A Medicine
October 24, 2016 by Miro Green Last Thursday the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) officially announced it was designating cannabidiol (CBD) – a non-psychoactive cannabis compound – as a medicine that can be administered for the purpose of “restoring, correcting, or modifying physiological functions.” This means that CBD products, which British law has been silent on until now, will be regulated like other medical products in the U.K., requiring medical “marketing authorization” before they can be sold. This is according to a letter sent to 18 CBD manufacturers shortly before the MHRA published its statement. Several voices here in the United States have been quick to report this as a step forward for marijuana reform, with Time referring to it as a “big win for the campaign to legalize cannabis” and Michael Collins of the Drug Policy Alliance saying this was “definitely a positive development.” The reaction fr...